GENE ONLINE|News &
Opinion
Blog

2021-08-25| Licensing

Vertex Inks $1.2B Pact with Feng Zhang Cofounded Startup to Develop Gene Therapies for Blood Diseases

by Tyler Chen
Share To
Source: Vertex

Building on their first collaboration 3 years ago, Vertex Pharmaceuticals (Vertex) and Arbor Biotechnologies strike a $1.2 billion deal to develop ex vivo engineered cell therapies with Arbor’s CRISPR gene-editing technology.

 

7 Programs Up for Development

The collaboration would allow the development of up to 7 potential programs with indications covering type 1 diabetes, sickle cell disease (SCD), beta-thalassemia, and other diseases. Feng Zhang, one of the pioneers of CRISPR technology, co-founded Arbor in 2016 and has developed seven gene-editing tools since then. The multi-selection of tools gave Arbor an edge in the gene therapy market.

The pair’s first partnership began in January 2019. The goal then was to discover programmable DNA endonucleases or nickases with high fidelity and catalytic activity for developing gene therapies that target cystic fibrosis and other 4 diseases.

As for Arbor, its pipeline revolves around three categories including liver diseases and two undisclosed diseases. Currently, the therapy for primary hyperoxaluria is in the process of lead optimization.

Related Article: New Era in Precision Medicine? Introduction & Overview of RNA Editing

Other than Arbor, Vertex is working with CRISPR Therapeutics founded by Jennifer Doudna, Affinia Therapeutic (Affinia), and other biotechs in the past couple of years.Vertex Bolsters Gene Therapy Development

The firm, in April 2021, expanded its gene therapy deal with CRISPR Therapeutics, first signed in 2015. Vertex has pumped in $1.1 billion to boost the development and commercialization of CTX001, the SCD and transfusion-dependent beta-thalassemia (TDT) gene therapy, and the first candidate in the collaboration.

The drug has won FDA’s regenerative medicine advanced therapy (RMAT), orphan drug, and rare pediatric disease designations and is now in Phase 1/2 clinical trial.

In April 2020, Vertex inked a $1.6 billion deal with Affinia to develop adeno-associated virus (AAV) capsids for better tissue tropism, manufacturability, and pre-existing immunity. It is expected to quicken the development of  Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and cystic fibrosis (CF) gene therapies. 

In a separate development, Vertex expanded collaboration with CRISPR Therapeutics, adding DMD and DM1 gene therapies to the list. Eyeing Exonics Therapeutics’ (Exonics) capability to R&D gene therapies on DMD and severe neuromuscular diseases, Vertex acquired the company for $245 million to help with the expansion of the previously mentioned deal.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BioMarin Wins First Gene Therapy Recommendation For Hemophilia A in Europe
2022-06-27
This One-Time Injection Could Cure AIDS
2022-06-21
FDA Approves Alnylam’s Rare Disease RNAi Therapeutic
2022-06-15
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
RESI Boston
Boston
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top